OS Therapies, Inc. , a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has been awarded a presentation slot at ...
In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates.
OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the US Food & Drug Administration ... and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored ...
The company is now preparing for discussions with the US Food & Drug Administration (FDA ... platform known as tunable ADC (tADC). This platform boasts a proprietary silicone linker technology ...
10d
While the spin-off is a key catalyst, OS Therapies’ core value driver remains its lead asset, OST-HER2, an immunotherapy targeting HER2-positive cancers. The company recently reported positive Phase ...
In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates.
SPECIAL PROMOTION - Original Price: $123000 ;Heavy Duty Trucks - CONVENTIONAL W/O SLEEPER;TADC TRACTOR;Eng Man-Detroit ... pls don't ask us to get anything else, we know it's just a scam!). This food ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback